. Author manuscript; available in PMC: 2012 Feb 26.

Published in final edited form as: Int J Cancer. 2011 Feb 1;128(3):597–607. doi: 10.1002/ijc.25371

Table 2.

CD8 Tcell immunophenotypic subgroups distribution by study group

Marker	HPV negative group^‡		Persistent HPV positive group^‡
Marker	N	Median %	N	Median %	p^*
CD3⁺CD8⁺^†	250	16.2	81	16	=0.98
CD69⁺CD8⁺^†	254	0.28	80	0.34	=0.15
CD25⁺CD8⁺^†	251	0.19	81	0.21	=0.92
HLADR⁺CD3⁺CD8⁺^††	250	37.6	81	42.1	=0.12
CD38⁺CD3⁺CD8⁺^††	250	6.6	81	6.3	=0.55
CD38⁺HLADR⁺CD3⁺CD8⁺^††	250	3.3	81	3.5	=0.71
CD38⁻HLADR⁺CD3⁺CD8⁺^††	250	32.9	81	37.4	=0.25
CD45RO⁺CD8⁺	252	58.6	80	62.9	=0.29
CD45RA⁺CD8⁺	251	77.0	80	76.0	=0.72
CD27⁺CD8⁺	251	51.3	81	47.5	=0.05
CD45RO⁺CD27⁺CD8⁺	252	33.1	81	31.2	=0.35
CD45RO⁺CD27⁻CD8⁺	252	23.2	81	27.1	<0.01
CD45RO⁺CCR7⁺CD8⁺	252	0.10	81	0.11	=0.33
CD45RO⁺CCR7⁻CD8⁺	252	58.4	81	62.2	=0.33
CD45RO⁺CD57⁺CD8⁺	251	19.1	81	22.8	=0.11
CD45RO⁺CD57⁻CD8⁺	251	36.1	81	33.9	=0.41
CD45RO⁺CD57⁻CD27⁺CD8⁺^†††	251	88.6	81	85.6	=0.08
CD45RO⁺CD57⁺CD27⁺CD8⁺^†††	251	11.4	81	14.4	=0.09
CD45RA⁺CD27⁺CD8⁺	252	30.3	81	29.4	=0.47
CD45RA⁺CD27⁻CD8⁺	252	41.1	81	41.9	=0.35
CD45RA⁺CCR7⁻CD8⁺	252	76.7	81	75.7	=0.64
CD45RA⁺CD57⁺CD8⁺	251	29.4	81	30.7	=0.33
CD45RA⁺CD57⁻CD8⁺	251	41.6	81	39.8	=0.33
CD45RA⁺CD57⁺CD27⁺CD8⁺^††††	251	8.1	81	9.4	=0.06
CD45RA⁺CD57⁻CD27⁺CD8⁺^††††	251	91.9	81	90.6	=0.07

^†

Markers expressed as percentage of total lymphocytes.

^††

Markers expressed as percentage of total CD3 positive CD8 positive lymphocytes.

^†††

Markers expressed as percentage of total CD27 positive, CD45RO positive within CD8 positive lymphocytes.

^††††

Markers expressed as percentage of total CD27 positive, CD45RA positive within CD8 positive lymphocytes. The rest of the markers are expressed as percentage of the CD8 positive lymphocytes

^‡

HPV group as defined in the methods section

Kruskal-Wallis test for equality of populations